Groundbreaking technological applications of nanotechnology in biomedicine: detecting emerging pathways from scientific and technological outputs by Mario Coccia & Ugo Finardi
Working
Paper
ISTITUTO DI RICERCA
SULL’IMPRESA E LO SVILUPPO
ISSN (print): 1591-0709
ISSN (on line): 2036-8216
C
o
n
si
g
li
o
 N
a
z
io
n
a
le
 d
e
ll
e
 R
ic
e
rc
h
e
cover new impa ceris 2010  26-01-2010  7:36  Pagina 1
                                                                        Coccia M., Working Paper Cnr-Ceris, N° 07/2012 
 
  
 
 
Copyright © 2012 by Cnr-Ceris 
All rights reserved. Parts of this paper may be reproduced with the permission of the author(s) and quoting the source. 
Tutti i diritti riservati. Parti di quest’articolo possono essere riprodotte previa autorizzazione citando la fonte 
 
 
WORKING PAPER CNR - CERIS 
RIVISTA SOGGETTA A REFERAGGIO INTERNO ED ESTERNO 
ANNO 14, N° 7  – 2012 
Autorizzazione del Tribunale di Torino  
N. 2681 del 28 marzo 1977 
ISSN (print): 1591-0709 
ISSN (on line): 2036-8216 
 
DIRETTORE RESPONSABILE 
Secondo Rolfo 
 
DIREZIONE E REDAZIONE 
Cnr-Ceris 
Via Real Collegio, 30 
10024 Moncalieri (Torino), Italy 
Tel. +39 011 6824.911 
Fax +39 011 6824.966 
segreteria@ceris.cnr.it 
http://www.ceris.cnr.it 
 
COMITATO SCIENTIFICO 
Secondo Rolfo  
Giulio Calabrese  
Elena Ragazzi 
Maurizio Rocchi 
Giampaolo Vitali 
Roberto Zoboli 
 
SEDE DI ROMA 
Via dei Taurini, 19 
00185 Roma, Italy 
Tel. +39 06 49937810 
Fax +39 06 49937884 
 
SEDE DI MILANO 
Via Bassini, 15 
20121 Milano, Italy 
tel. +39 02 23699501 
Fax +39 02 23699530 
 
SEGRETERIA DI REDAZIONE 
Enrico Viarisio 
e.viarisio@ceris.cnr.it 
 
DISTRIBUZIONE 
On line: 
http://www.ceris.cnr.it/index.php?option=com_content&task=section&id=4&Itemid=64 
 
FOTOCOMPOSIZIONE E IMPAGINAZIONE 
In proprio 
Finito di stampare nel mese di Maggio 2012 
 
Coccia M., Working Paper Cnr-Ceris, N° 07/2012                                                                         
  
Groundbreaking technological applications  
of nanotechnology in biomedicine: detecting 
emerging pathways from scientific and 
technological outputs 
 
Mario Coccia* 
CNR-CERIS 
 
National Research Council of Italy, 
via Real Collegio, n. 30, 10024 Moncalieri (To), Italy 
Tel.: +39 011 68 24 925 
Mail: m.coccia@ceris.cnr.it 
 
Ugo Finardi** 
University of Torino and CNR- CERIS  
 
Department of Chemistry and  NIS - Nanostructured Interfaces 
and Surfaces Centre of Excellence 
via P. Giuria, n. 7, 10125 Torino, Italy 
Tel.: +39011-6708385 
Mail: ugo.finardi@unito.it 
 
ABSTRACT: The purpose of this paper is to measure and analyze the rate of scientific and technological 
advances of nano-technological research in biomedicine. The approach, based on models of growth, shows the 
current evolutionary trends of nano-research that may underpin future patterns of technological innovation in 
biomedicine. In particular, results show that biosensors, nanoparticles, quantum dots, carbon nanotube and 
nanomicelle have innovative applications in diagnostics and target therapies that have been generating a 
revolution in clinical practice. The present study also shows two main implications of determinants that have 
been supporting continuous application of nanotechnology in biomedicines such as the patterns of technological 
innovation driven by converging research fields and a learning process. These factors have been paving the way 
to innovative nanomedical drugs applied in biomedicine that lead to longer, better and healthier living of patients 
and therefore of societies. 
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INTRODUCTION 
cientific research and patents are crucial 
competitive assets of nations in the 
current knowledge era. They are 
generated within the national system of 
innovation1 in order to support the “competitive 
advantage” of countries (Porter, 1990) (see also 
Aghion and Howitt, 1998; Coccia, 2008). 
Scientific research focused on bio-
nanotechnology is a current vital research field 
that has been supporting innovation and change 
in modern biomedicine and biomedical 
engineering (Islam and Miyazaki, 2010; Rafols 
and Meyer, 2007; Rafols and Meyer, 2010). In 
fact, nanostructured materials, also in connection 
with biomolecules, have a high potentiality of 
development for biomedical purposes by 
applications in new therapeutic instruments, 
diagnostic methodologies, etc. (cf. Lim et al., 
2010). No and Park (2010) argue that the 
interaction of biotechnology and nanotechnology, 
using patent citations, may provide main signals 
for future patterns in nano-biomedicine (cf. 
Bárcena et al., 2009; Sylvester and Bowman, 
2010).  
The purpose of this paper is to analyze the 
evolutionary growth of knowledge in 
nanotechnology research by a model that 
measures and assesses the rate of scientific and 
technological advances in biomedicine and 
nanomedicine. This approach uses data of articles 
and patents, and provides main information to 
understand current leading scientific areas in the 
field of nanotechnology that have been 
generating a revolution in clinical practice. In 
particular, this technological analysis is important 
to explore future nano-biomedical pathways that 
will improve human health and quality of life. 
Next section describes the theoretical 
framework, showing the most important features 
of nanotechnologies applied to the bio-medical 
field. The third section describes data mining 
strategy and research methodology, while the 
                                                     
1  The national system of innovation (NSI) refers to the 
complex network of agents, policies, and institutions 
supporting the process of technical advance in an 
economy (Lundvall, 1992). The narrow definition of NSI 
would include the subsystem research sector represented 
by universities, research laboratories, while the broad NSI 
includes many subsystems such as finance, firms, 
government, and so on. The efficiency of this broad NSI 
supports economic growth patterns. 
fourth part shows the main findings. The last 
section discusses the results, showing trends that 
seem to be emerging in nanotechnology applied 
in biomedicine. 
1. THEORETICAL FRAMEWORK 
Biomedicine is one of the key scientific fields 
where nanotechnologies are providing vital 
innovative applications. Nanostructured materials 
show high sensibility, stability and 
biocompatibility and are applied to improve the 
performance of diagnostic or therapeutic tools2. 
Kim et al. (2010, p. 2434) state: 
Nanomaterials are now being designed to aid 
the transport of diagnostic or therapeutic agents 
through biologic barriers; to gain access to 
molecules; to mediate molecular interactions; and 
to detect molecular changes in a sensitive, high 
throughput manner. In contrast to atoms and 
macroscopic materials, nanomaterials have a high 
ratio of surface area to volume as well as tunable 
optical, electronic, magnetic, and biologic 
properties, and they can be engineered to have 
different sizes, shapes, chemical compositions, 
surface chemical characteristics, and hollow or 
solid structures. These properties are being 
incorporated into new generations of drug-
delivery vehicles, contrast agents, and diagnostic 
devices. 
The present paper analyzes the scientific and 
technological evolution of knowledge of some 
nanotechnologies in biomedicine. Thus, in order 
to better frame the research design, we describe, 
briefly, the main characteristics of some vital 
nanotechnological research topics that we are 
going to analyze to pinpoint technological 
trajectories. 
Nanoparticles for therapeutics and diagnostics 
Nanoparticles (NPs) are a key element for the 
development of nanotechnologies in the 
biomedical field (Chen et al., 2011; He et al. 
2010). NPs are nanoscopic spheres ranging in 
diameter up to some tenths of nanometers3 that 
can be made of metals, metallic salts or oxides, or 
can have a biological origin. Several NPs are 
used as contrast agents in Magnetic Resonance 
Imaging (in vivo anatomical imaging) for 
                                                     
2  Cf. Hu et al., 2011; Sekhon et al., 2010; Sekhon et al., 
2010b; Willner and Willner, 2010. 
3  A nanometer (nm) is equal to one millionth of millimeter.  
S 
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diseases of the vascular system and of the heart. 
Iron oxide nanoparticles present peculiar 
magnetic properties (superparamagnetism). Up-
to-date research has showed that Iron oxide 
nanoparticles are non toxic, have minimal impact 
on cell viability and function (cf. Bárcena et al., 
pp. 591ff). NPs are also able to target selectively 
the object of the analysis due to the addition of 
specific surfactants. Some NPs can also fluoresce 
and are applied as probes for optical imaging 
techniques. In fact, Gold nanoparticles or rare 
earth doped particles fluoresce once irradiated 
with particular wavelengths, such that they are 
used for optical imaging of proteins and genes. 
Several dye-containing or dye-doped 
nanoparticles – such as Silica nanoparticles or 
Calcium phosphate nanoparticles – are important 
for in-vivo or ex-vivo near infrared fluorescence 
imaging of cancers (Coto-García et al., 2011). 
Quantum dots for diagnostics and therapeutics 
A specific subset of NPs is represented by 
Quantum Dots (QDs) (Obonyo et al., 2010; 
Byers et al., 2011; Rosenthal et al., 2011). QDs 
(which have generally a diameter of 2 - 10 nm) 
are produced including a spherical core of a 
semiconductor in a shell of another 
semiconductor with a different band gap. This 
allows to control their electronic and light 
emission properties. The bioconjuation of the 
surface of QDs with biomolecules (e.g. 
antibodies, oligonucleotides, DNA, etc.) gives the 
property of targeting them onto specific locations 
in the body to kill, for example, tumor cells. QDs 
can also be used in diagnostics. Irradiation with 
specific wavelength generates the fluorescence of 
QDs that is an effective approach to find out the 
location of solid cancers. QDs are also used for 
therapeutic purposes, for instance in 
Photodynamic Therapy: irradiation with low 
energy electromagnetic waves allows QDs to 
excite oxygen molecules present in the body via 
an electronic process; excited oxygen is very 
reactive and causes the death of tumor cells and 
not of normal cells. 
Cyanine dies-loaded nanoparticles for 
diagnostics 
A relevant position in this scientific research is 
played by Cyanine dyes (Miletto et al., 2010; 
Mortati et al., 2011; Alberto et al., 2009), a class 
of organic colored molecules presenting strong 
fluorescence features and high biocompatibility 
towards the human body (Shi et al., 2010). 
Carbon nanotubes as drug carrier 
Nanostructured materials are also used for 
carrying drugs: porous inorganic nanoparticles 
can be loaded with effective drugs, which are 
contained into organic nanomicelles that by apt 
bioactive systems target body cells presenting 
illness. Carbon nanotubes are a typology of 
nanostructured materials studied to delivery 
drugs against cancers (Ezzati Nazhad Dolatabadi 
et al., 2011). In fact, their tubular structure allows 
both carrying drugs and protecting them towards 
external agents. More in general therapeutic 
applications involving nanotechnological 
materials combined with cytotoxic 
(antineoplastic or chemotherapies) agents are a 
key area of development for science and 
technology (Shapira et al., 2011). 
Nano-biosensors 
Biosensors are a promising application of 
nanotechnology, as they play a critical role for 
modern biomedical technologies. In particular, 
biosensors are, basically, devices able to detect 
specific biological molecules and to convert their 
presence in an electric signal that can be analyzed 
for diagnosis (Bounichy and Mousa, 2011; 
Sanvicens et al., 2011). A key application is the 
detection of cancers in the human body as well as 
to find out pharmaceuticals in concentrations 
well beyond those detectable by traditional 
methods. Biosensors in diagnostics rely much on 
modern nanotechnological applications: for 
instance the use of single wall carbon nanotubes 
has enhanced the ability of detection of 
electrochemical biosensors that are able to find 
out cancers and their metastases. 
Gold nanoparticles for Plasmon Photothermal 
Therapy 
Another main advanced therapy for cancer, 
based on nanostructured/nanodimensioned 
materials, is the Plasmon Photothermal Therapy.  
In this case, Gold nanoparticles and Gold 
nanorods4, because of the electronic structure of 
the particle/rod, have the feature of heating 
themselves when exposed to strong 
electromagnetic radiations, like those emitted by 
lasers (Ratto et al., 2011; Ungureanu et al., 
                                                     
4  Nanorods are a specific morphology of nanoscaled objects. 
   The main difference from nanoparticles is their elongated 
   shape. Each of their dimensions range from 1 to 100 nm. 
   They may be synthesized from metals or semiconducting 
   materials. 
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2011). This biomedical procedure uses the heat 
for killing cancer cells (El-Sayed et al., 2006). 
Nanoparticles for immunotherapy 
Immunotherapy is another new frontier for 
future therapeutic treatment of cancer. In 
particular, the combination of nanotech objects 
and lymphocytes, such as T-cells5, may be vital 
for new applications of these methods for 
effective cancer treatments (Hamdy et al., 2011; 
Hung et al., 2011). 
Some edge areas of bio-nano-medical 
applications (closer to molecular biology) are still 
at the stage of first experimental trials, such as 
the combination between nanovector and si-RNA 
or mi-RNA6. 
These main topics of nanotechnology play a 
vital role in biomedicine. Next section describes 
the methodology to investigate their rates of 
growth in order to understand the current patterns 
of development that may drive the future therapy 
and diagnosis in medical practice.  
2. DATA MINING STRATEGY AND 
METHODOLOGY OF RESEARCH  
This paper uses Scopus (Scopus 2011) database 
and data mining is performed with a series of 
queries based on complex search subjects of 
keywords and Boolean operators. Data mining is 
performed in the time horizon 2000 – 2010 for 
scientific research products (e.g. articles) and for 
patents across key nano-bio-medical topics. Data 
on scientific products, which represent a proxy of 
scientific activity, are retrieved via the 
“Advanced search” window of Scopus website, 
using the “Article title, abstract, keyword” tag in 
the search window. Data on patents that indicate 
a proxy of technological activity, are retrieved in 
the SciVerse Scopus instrument with a full text 
 
 
                                                     
5  T cells or T lymphocytes belong to a group of white blood 
cells known as lymphocytes, and play a central role in 
cell-mediated immunity. The abbreviation T stands for 
thymus, since this is the principal organ responsible for 
the T cell's maturation.  
6 Small interfering RNA (siRNA), sometimes known as 
short interfering RNA or silencing RNA, is a class of 
double-stranded RNA molecules, 20-25 nucleotides in 
length, that play a variety of roles in biology. MicroRNAs 
(miRNAs) are short ribonucleic acid (RNA) molecules, 
on average only 22 nucleotides long and are found in all 
eukaryotic cells, except fungi, algae, and marine plants. 
query7. Tests are made before performing the 
final queries. Syntax of these queries is checked 
in order to obtain best results in terms of number 
of occurrences. The queries are dived in two 
main groups. The first group concerns general 
terms related to scientific fields of nano-bio 
medicine. The aim is to measure the general rate 
of scientific and technological growth of 
nanotechnology in biomedical sciences. The 
second group is focused on specific analysis of 
subfields or techniques: the bio-nano-medicine 
applied mainly in diagnostic and therapeutic 
techniques. The queries of this group are able to 
provide data to analyze specific trends of several 
important scientific-technological topics in nano-
bio-medicine, as well as to explore specific topics 
that are (either or both): 
- in some way on the edge of basic research 
activities; 
- very promising for future results in biomedical 
applications; 
- liable of generating a huge quantity of 
innovative activities. 
Appendix 1 presents a short description of 
these queries. 
The vast sample, represented by 42,800 
occurrences of articles and 213,732 of patents, is 
the basis to apply the model in order to measure 
the rate of scientific and technological advances 
of nanotechnology in biomedicine. First of all, 
the data has been analyzed by descriptive 
statistics and a correlation analysis. After that, the 
following assumptions are stated to apply the 
model:  
1. aP is the number of articles/patents in the 
specific research field at 2000  
2. tP is the number of articles/patents in the 
specific research field at 2010 
 
                                                     
7 Technology is based on inventions and innovations. 
Invention is a commercially promising product or service, 
based on new science and/or technology that meets the 
requirements for a patent application and/or the patent is 
already granted. On the other hand, innovation, which 
already has a valid and granted patent, is the successful 
entry of a new science or technology-based product into a 
particular market. In particular, innovations are protected 
by patents, which indicate the current innovation of 
industries and also commercially promising inventions.  
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3. t is the period analyzed and it is equal to 10 
years 
4. this basic scientific research might generate 
over the Forecast horizon (e.g. from 2011 
onwards) new patterns of nano-technological 
innovations in biomedicine. 
5. articles are a proxy of the scientific activity, 
whereas patents are a proxy of the technological 
activity of the research field.  
Since these critical scientific areas have a 
considerable acceleration in their production 
activity, the model is based on an exponential 
function (cf. Livi Bacci, 1999, chp. 3):  
rt
t ePP 0   
where e is the base of natural logarithm 
(2.71828…). 
 
Hence t rt e
P
P

0
;   
tr
P
P
Log t 
0
;  
 
.
t
P
P
Log
r
t









0                           [1] 
r= rate of scientific and technological advances 
of nano-research in biomedicine.  
This model can be used to assess the 
evolutionary growth of knowledge in the short 
run8 and can offer an analytical framework for 
understanding the current patterns of nano-
technological innovations that can drive the 
future progress in biomedicine in fast-changing 
scenarios. 
3. FINDINGS AND DISCUSSION 
Table 1 shows, ceteris paribus, the rates of 
growth of general nanotechnology trends in 
biomedicine. All rates are rather high; in 
particular the rates based on the use of 
biocompatible materials show the highest rate of 
growth both in journal articles (56.93%) and 
patents (46.72%). This means that these key 
research areas have been generating an 
 accumulation of knowledge that can underpin 
the pathways of innovative applications of 
nanotechnology in biomedicine.  
 
 
Table 1: rates of growth in MAIN nano-research fields in biomedicine over 2000-2010 
Main nanotechnology research fields in biomedicine 
Rate of scientific 
growth (articles) 
% 
Rate of technological 
growth (patents) 
% 
1. (bionanotechnology OR (bio nanotechnology) OR 
(bionano technology) OR nanobiotechnology OR (nano 
biotechnology) OR (nanobio technology)); occurrences: 
3426 articles, 13,542 patents 
37.39 21.08 
2. (nanobiomaterial OR (nano biomaterial) OR (nanobio 
material) OR bionanomaterial OR (bio nanomaterial) OR 
(bionano material)); occurrences: 1183 articles, 1784 
patents 
49.56 31.31 
3. ((biocompatible nanomaterial) OR (biocompatible 
nanomaterials)); occurrences: 877articles, 499 patents 56.93 46.72 
4. ((biomedical AND nano) OR (bio AND medical AND 
nano) OR (bionano AND medical) OR (biomedicine AND 
nano) OR (bio AND medicine AND nano) OR (bionano 
AND medicine)); occurrences: 7554 articles, 30,563 patents 
43.94 27.38 
 
 
 
 
 
 
    ___________________________ 
8    See Diebold (2004) for a general description of other 
forecasting methods. 
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Instead, table 2 shows, ceteris paribus, the rates 
of scientific/technological advances of nano-
research in specific biomedical subfields of 
diagnostics and therapeutics. Average rate of 
scientific advances across these key research 
fields is 37.6% (st.dev. 10.4), whereas the 
average rate of technological advances is 23.8% 
(st. dev. 2.5). Of course, coefficient of correlation 
between rates of scientific and technological 
growth (of nano-bio-medicine applied in 
diagnostics and therapeutics) is positive and 
equal to 55.5% (sig. at the 0.05 level). This 
means that scientific and technological advances 
have similar and interwoven patterns of growth 
within the “techno-economic paradigms of 
nanotechnology” (cf. also Coccia et al., 2011). 
Although table 1A (appendix) shows that some 
converging research fields have a higher number 
of patents and/or articles, the rate of growth is 
lower than in smaller research fields (cf. Table 
2). In fact, smaller research fields have a low 
number of occurrences because they are at the 
early stage of development, though they are 
characterized by high intensity of knowledge 
growth, representing promising emerging 
nanotechnologies for biomedical sciences. 
 
Table 2 –Rate of scientific and technological advances of vital biomedical nanotechnology  
over 2000-2010 
Nano-research research fields in biomedicine 
% Rate of scientific 
growth 
(articles) 
% Rate of technological 
growth 
(patents) 
Vital nanotechnology for diagnostics   
((biosensor OR (bio sensor)) AND (nanotechnology OR 
nanotech)) 39.93 32.36 
(((quantum dot) OR (quantum dots)) AND (diagnostic OR 
diagnosis)) 38.59 20.73 
(magnetic AND (nanoparticle OR nanoparticles) AND 
imaging) 35.09 25.16 
((nanoparticle OR (nano particle) OR nanoparticles OR 
(nano particles)) AND (diagnostic OR diagnosis)) 33.34 19.94 
(cyanine AND (nano*) AND (imaging OR (optical 
imaging))) 31.35 10.44 
((nano*) AND (fluorescence imaging))  28.92 16.45 
(((quantum dot) OR (quantum dots)) AND (imaging OR 
(optical imaging))) 27.74 21.20 
Nanovector 15.07 8.41 
Vital nanotechnology for therapeutics    
(((quantum dot) OR (quantum dots)) AND (therapeutic OR 
therapy)) 57.76 21.77 
((tumor OR cancer) AND (quantum dot)) 53.88 20.11 
(nanomicelle) 53.65 -- 
(((carbon nanotube) OR (carbon nanotubes) OR nanotube 
OR CNT) AND (drug delivery))) 53.29 26.74 
(plasmon photothermal therapy) 41.65 25.58 
((nanotechnology) AND (cytotoxic drugs)) 37.79 34.84 
((nanotechnology OR nanoparticle OR nanoparticles) AND 
(T-cell)) 37.61 53.71 
((nanoparticle OR (nano particle) OR nanoparticles OR 
(nano particles)) AND (therapeutic OR therapy)) 35.05 18.68 
((nanotechnology) AND (mi-RNA)); 34.66 -- 
((nanotechnology) AND (si-RNA)); 32.97 -- 
(RNA oligonucleotide nanoparticle delivery);  32.60 28.69 
((nanoparticle OR (nano particle) OR nanoparticles OR 
(nano particles)) AND (drug delivery)) 30.47 19.29 
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Table 2 shows that in diagnostics the higher 
rate of scientific growth is given by nanotech 
applications to biosensors (nano-biosensoring, 
39.9% for articles and 32.36% for patents) and by 
the use of Quantum Dots (38.59% for articles and 
20.73% for patents). The application of magnetic 
nanoparticles for imaging techniques (35.09%) is 
another key area with high rate of scientific 
growth (measured by articles in journals); this 
result is reinforced by the high rate of 
technological advances measured by patents 
(25.16%). Bárcena et al. (2009, p. 591) state that: 
“superparamagnetic iron oxide nanoparticles 
were found nontoxic and used as magnetic 
resonance imaging contrast agents, in molecular 
and cellular imaging applications […] drug 
delivery via magnetic targeting, hyperthermia, 
and labeling/tracking of stem cells have also been 
explored as potential therapeutic options.” 
We ascertain that rates of scientific advances 
for therapeutic applications are higher (41.7%) 
than diagnostic applications (31.25%), whereas 
rates of technological advances are 19.33% 
(diagnostics) vs. 27.7% (therapeutics). Some 
topics in therapeutics do not have patenting 
activity because the nano-biotechnology 
applications are at the early stage of development 
(mainly in molecular biology - related research 
fields). The highest rates of scientific advances 
(measured by articles in journals) are for 
therapeutic applications of Quantum Dots 
(57.29% and 53.88%), carbon nanotubes for drug 
delivery (53.29%) and nanomicelles (53.65%). 
Nanomicelles have a polymeric structure to 
which ligands can be bound to target, for 
instance, specific viruses; they are mainly applied 
for destroying viruses and have generating a main 
shift of the paradigm in antiviral therapies 
changing the clinical practice. The scientific 
growth of therapeutic applications of magnetic 
nanoparticles is more than 35%. Bárcena et al. 
(2009, p. 612) describe some vital applications 
such as: “the magnetic fluid hyperthermia is a 
treatment for the eradication of cancer tissues 
using an alternating magnetic field. The magnetic 
waves are not absorbed by living tissue and 
permeate throughout the body.” Plasmon 
Phototermal Therapy also shows a high growth in 
scientific and technological advances (41.65% 
and 25.58%, respectively).  
Another high rate of technological growth 
(measured by patents) is by the edge biomedical-
nano-research based on the combination of 
nanomaterials with T-cells (53.71%), applied 
mainly for cancer immunotherapy, and the use of 
nanotech materials associated to cytotoxic agents 
(34.84%). In particular nanomaterials in 
combination with T-cell biology are an apt 
technique to produce treatments that evade the 
immune system and deliver localized therapeutic 
payloads, minimizing the adverse reactions. 
These main nano-research fields are driving 
target cancer therapies in order to overcome drug 
resistance with traditional chemotherapy 
approaches. This nanomedicine based on new 
nanovehicles has been generating a revolution in 
modern clinical practice to treat a variety of 
cancers. Shapira et al. (2011, p. 150) claim that 
“NPs are being exploited for selective drug 
delivery to tumor cells, to cancer stem/tumor 
initiating cells and/or to the supportive cancer 
cell microenvironment, i.e. stroma or tumor 
vasculature.” 
These current rates of evolutionary growth of 
knowledge based on journal articles and patents 
allow to show insights in order to pinpoint some 
leading research fields of nanotechnologies that 
may drive future innovative application of 
nanotechnologies in bio-nanomedicine.  
4. CONCLUDING REMARKS 
This research shows how nanotechnologies 
have been affecting biomedicine with innovative 
applications for therapy and diagnosis. In fact, 
several specific nanomedical applications are 
effective strategies in diagnostics and 
therapeutics for delivering chemotherapeutic 
drugs, chemosensitizers, drug resistant proteins, 
etc. In addition, with the use of nanotechnology 
in biomedicine, cytotoxic drugs can be delivered 
to cancer sites more effectively and with lesser 
adverse reactions than traditional techniques. We 
review our main findings for nano-research and 
patents in biomedicine showing how the current 
fast-changing technological scenarios are 
characterized by following vital patterns: 
1. In general: the rates of scientific growth of 
nanostructured and biocompatible materials in 
biomedicine (Table 1) are higher than others; 
2. In particular: nanotechnology applied in 
diagnostics may be driven mainly by 
biosensors, nanoparticles, nanomicelles, and 
Quantum Dots; for instance, magnetic 
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nanoparticles are mainly applied for magnetic 
resonance imaging, gastrointestinal tract 
imaging, liver and spleen images, lymph 
nodes imaging, etc.  
3. As far as nanotechnologies applied for 
therapeutics are concerned, leading roles will 
be played by: Quantum Dots, which have 
scientific growth rates greater than in 
diagnostic techniques, because of their 
effective applications to treat cancers, whereas 
their patenting activity lags behind other 
applications; nanotech applications to deliver 
cytotoxic drugs, which have also a high rate 
of growth in patenting activities (34.84%). 
Current cancer therapies based on traditional 
chemotherapy agents have several limitations 
because of drug resistance and new anticancer 
drugs based on nanomedicine are rapidly 
evolving, overcoming limitations of standard 
chemotherapy agents. In fact, NPs in 
combination with a cytotoxic drug can 
overcome the drug resistance proteins and 
enable to treat with effectiveness tumor and 
its metastases. 
Other emerging biomedical-nano-research 
fields are:  
- Nanotech applications with the use of T-cells, 
that have a high technological rate of advance 
(53.7%) because of innovative applications to 
treat cancers; 
- Drug delivery techniques performed with 
carbon nanotubes as carriers; 
- Converging molecular biology and 
nanotechnology (nanovector and siRNA or 
miRNA, RNA oligonucleotide nanoparticle 
delivery); such converging nano-research is at 
the stage of trials and shows lower growth rates, 
though they have promising future applications 
in biomedicine. In particular they  
may play a main role as a new class of 
therapeutics based on nanoparticle drug 
delivery system. For instance, an innovative 
application is to treat the brain ischemic insult 
by carbon nanotube-mediated siRNA silencing 
(CNR 2011). 
These results show that all analyzed new nano-
research topics (including very specific areas 
such as Cyanine Dyes in optical imaging, 
Plasmon Phototermal Therapy or molecular 
biology-related areas) have high rates of growth 
driven mainly by current intensive scientific 
advances that create the background for 
underpinning technological advances in 
biomedicine. 
The present study shows also that some 
nanotechnologies, such as magnetic 
nanoparticles, are playing a key role in diagnosis, 
though their applications for target therapy are 
still in a preliminary phase of development (cf. 
Bárcena et al., 2009, pp. 162 ff). In fact, a lot of 
progress in the functionalization of these 
nanoparticles is focused on widening their 
diagnostic ability, though magnetic drug 
targeting by nanoparticles still presents several 
problems associated to humans. In addition, these 
scientific and technological advances of 
nanotechnology applied for biomedicine take 
place in several phases and there are significant 
time lags between the acquisition of information 
in clinical research and the development/ 
improvement of new applications of 
nanomedicine in clinical practice. In addition a 
fruitful role in developing innovative applications 
of nanotechnology in biomedicine is played by 
continuous learning process between clinical 
research and clinical practice in collaboration of 
medical staff and patients (Coccia, 2012). In 
particular, the steps of R&D are interwoven and 
blockbusters are best pursued in cooperation with 
end users (patients). It is important to note that 
advances of nanotechnology in biomedicine 
havebeen generating innovative drugs and 
diagnostic tools driven mainly by:  
a) converging of different research fields and 
technologies such as the fruitful interaction 
between nanotechnology and molecular biology, 
which is a considerable boost to innovations in 
biomedicine that improve the clinical practice to 
treat drug resistant illnesses;  
b) learning processes driven by the acquisition of 
skills through the interaction between clinical 
research and clinical practice based on 
participation of patients and medical staff 
(Coccia, 2012). 
The continuous technical progress in 
biomedicine is supported by high intensity of 
scientific and technological knowledge growth of 
nanotechnology trajectories in association to 
advances in basic biomedical research, genomics, 
genetics etc. that has been paving revolutionary 
applications in clinical practice that will lead to 
longer, better and healthier living of modern 
societies. 
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APPENDIX 
SHORT DESCRIPTION OF SEARCH TERMS 
 
Diagnostic applications involving the use 
of nanotech items 
- ((biosensor OR (bio sensor)) AND 
(nanotechnology OR nanotech)): this 
query explores the relations existing 
between biosensors and applications of 
nanotechnologies. 
- (((quantum dot) OR (quantum dots)) 
AND (diagnostic OR diagnosis)): 
quantum dots (as above described) 
application in any diagnostic technique is 
explored by this query. 
- (magnetic AND (nanoparticle OR 
nanoparticles) AND imaging): The use of 
magnetic nanoparticles in specific 
bioimaging techniques for diagnostic 
use; 
- ((nanoparticle OR (nano particle) OR 
nanoparticles OR (nano particles)) AND 
(diagnostic OR diagnosis)): explores the 
use of nanoparticles for diagnostic 
purpose. 
- (cyanine AND (nano*) AND (imaging 
OR (optical imaging))): the use of a 
specific type of fluorescent dyes (cyanine 
dyes) coupled to the use of 
nanostructured materials (mostly 
nanoparticles or nanotubes) for imaging 
diagnostic techniques; 
-  ((nano*) AND (fluorescence imaging)): 
this query explores the use of 
nanostructured materials (nanoparticles, 
nanotubes) in the diagnostic techniques 
involving fluorescence imaging 
-  (((quantum dot) OR (quantum dots)) 
AND (imaging OR (optical imaging))): 
in this case the search term is more 
specific with respect to the previous one, 
and collects data on the exploitation of 
quantum dots in all imaging diagnostic 
techniques (either optical or not). 
 
 
 
Therapeutic applications (e.g. against 
tumors) involving the use of nanotech 
items 
- (((quantum dot) OR (quantum dots)) 
AND (therapeutic OR therapy)): the use 
of quantum dots for therapeutic purposes. 
- ((tumor OR cancer) AND (quantum 
dot)): the use of above described 
quantum dots in cancer diagnosis and 
therapy; 
- (((carbon nanotube) OR (carbon 
nanotubes) OR nanotube OR CNT) AND 
(drug delivery)): the use of carbon 
nanotubes for targeted drug delivery. 
- (plasmon photothermal therapy): the 
above described thermal therapy 
involving nanostructures. 
- ((nanotechnology) AND (cytotoxic 
drugs)): the object of the query is the 
combined used of nanotechnology 
retrieval and cytotoxic drugs for the cure 
of cancer; 
- ((nanotechnology OR nanoparticle OR 
nanoparticles) AND (T-cell)): this query 
explores the combination of nanotech 
objects with T-cell (a type of 
lymphocytes) for the cure of cancer. 
-  ((nanoparticle OR (nano particle) OR 
nanoparticles OR (nano particles)) AND 
(therapeutic OR therapy)): the use of 
nanoparticles for therapies. 
- ((nanotechnology) AND (mi-RNA)), 
((nanotechnology) AND (si-RNA)), 
(RNA oligonucleotide nanoparticle 
delivery): these queries explore topics 
combining molecular biology and 
nanotechnology for therapeutic purposes; 
- ((nanoparticle OR (nano particle) OR 
nanoparticles OR (nano particles)) AND 
(drug delivery)): the use of nanoparticles 
for targeted drug delivery. 
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Table 1A – Number of occurrences of vital biomedical nanotechnology research fields over 2000-2010 
Nano-research research fields in biomedicine 
Occurrences  
(articles) 
Occurrences  
(patents) 
Vital nanotechnology for diagnostics   
((biosensor OR (bio sensor)) AND (nanotechnology OR 
nanotech)) 1404  1303 
(((quantum dot) OR (quantum dots)) AND (diagnostic OR 
diagnosis)); 1050 7389 
(magnetic AND (nanoparticle OR nanoparticles) AND 
imaging) 2890 10,615 
((nanoparticle OR (nano particle) OR nanoparticles OR 
(nano particles)) AND (diagnostic OR diagnosis)) 3771 30,105 
(cyanine AND (nano*) AND (imaging OR (optical 
imaging))) 75 3444 
((nano*) AND (fluorescence imaging))  3363 28,753 
(((quantum dot) OR (quantum dots)) AND (imaging OR 
(optical imaging))) 2592 9430 
Nanovector 36 46 
Vital nanotechnology for therapeutics    
(((quantum dot) OR (quantum dots)) AND (therapeutic 
OR therapy)); 617 6028 
((tumor OR cancer) AND (quantum dot)) 1076 4205 
(nanomicelle) 10 10 
(((carbon nanotube) OR (carbon nanotubes) OR nanotube 
OR CNT) AND (drug delivery))) 1045 2806 
(plasmon photothermal therapy)  78 76 
((nanotechnology) AND (cytotoxic drugs)) 152 478 
((nanotechnology OR nanoparticle OR nanoparticles) 
AND (T-cell)); 340 1324 
((nanoparticle OR (nano particle) OR nanoparticles OR 
(nano particles)) AND (therapeutic OR therapy));  6466 39,227 
((nanotechnology) AND (mi-RNA));  109 --- 
((nanotechnology) AND (si-RNA));  10 --- 
(RNA oligonucleotide nanoparticle delivery);  166 458 
((nanoparticle OR (nano particle) OR nanoparticles OR 
(nano particles)) AND (drug delivery)) 10,042, 34,421 
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